NACC family member 2Genealiases: BEND9 · BTBD14 · BTBD14A · BTBD31 · NAC-2 · RBB
Q-omics provides the consensus-scored NACC2 profile across patient tissues and cancer cell-line models. NACC2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, NACC2 is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, NACC2 RNA expression shows 19,423 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and BLCA as cancer lineages where NACC2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NACC2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NACC2 survival associations across molecular data types. NACC2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NACC2 RNA expression–survival associations across cancer types. High NACC2 expression shows unfavorable associations in UVM, CESC, LUSC, LIHC and BLCA, but favorable associations in KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for NACC2 RNA expression.
This table summarizes NACC2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for NACC2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NACC2 shows lower tumor expression in BLCA, UCEC, LUSC, BRCA and KIRC and higher tumor expression in LIHC. The BLCA box plot shows higher NACC2 RNA expression in normal versus tumor tissue (log2 FC = −3.120, t-test p < 0.001).
This table shows molecular features associated with NACC2 in patient tissues and cancer cell lines. In patient samples, NACC2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, NACC2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OVARY and SOFT_TISSUE.
